Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rivaroxaban for Improvement of Thromboembolism Outcomes in Patients With Multiple Myeloma on Lenalidomide-based Therapy: RithMM Trial

NCT03428373 is registered in ClinicalTrials.gov with London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's as lead sponsor.

NCT NCT03428373
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03428373 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rivaroxaban for Improvement of Thromboembolism Outcomes in Patients With Multiple Myeloma on Lenalidomide-based Therapy: RithMM Trial
Lead sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase
Phase 2/3
Overall status
Unknown status
Start date
January 17, 2019
Completion date
September 30, 2024
Enrollment
57 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma in relapse, multiple myeloma progression, multiple myeloma stage i, multiple myeloma stage ii, multiple myeloma stage iii, multiple myeloma with failed remission